-
公开(公告)号:EP3050880B1
公开(公告)日:2019-06-19
申请号:EP14849754.8
申请日:2014-09-28
申请人: Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人: XIAO, Dengming , ZHU, Yan , HU, Yuandong , WANG, Huting , LI, Jijun , PENG, Yong , ZHANG, Hui , LUO, Hong , KONG, Fansheng , HAN, Yongxin
IPC分类号: C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , A61K31/517 , A61K31/5377 , A61P35/00
-
公开(公告)号:EP3235819A1
公开(公告)日:2017-10-25
申请号:EP15869312.7
申请日:2015-12-15
申请人: Centaurus BioPharma Co., Ltd. , Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人: ZHU, Li , XIAO, Dengming , HU, Yuandong , DAI, Liguang , DUAN, Xiaowei , SUN, Yinghui , PENG, Yong , KONG, Fansheng , LUO, Hong , HAN, Yongxin , YANG, Ling , WANG, Shanchun
IPC分类号: C07D487/04 , A61K31/519 , A61K31/5377 , A61P35/00
摘要: The present application relates to the field of pharmaceutical chemistry, and in particular, to a pyrrolopyrimidine compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the pyrrolopyrimidine compound represented by general formula (I), pharmaceutical compositions and an application of the pyrrolopyrimidine compound in treating diseases mediated by Janus Kinase.
摘要翻译: 本申请涉及药物化学领域,特别涉及通式(I)所示的吡咯并嘧啶化合物,其立体异构体或其药学上可接受的盐。 本发明还涉及通式(I)代表的吡咯并嘧啶化合物的制备方法,药物组合物和吡咯并嘧啶化合物在治疗由Janus激酶介导的疾病中的用途。
-
公开(公告)号:EP3330263B1
公开(公告)日:2020-11-18
申请号:EP16829888.3
申请日:2016-07-29
申请人: Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人: WANG, Shulong , ZHAO, Na , LIU, Xijie , HU, Yuandong , ZHANG, Hui , LUO, Hong , PENG, Yong , XIAO, Dengming , HAN, Yongxin , ZHANG, Xiquan , TIAN, Xin
IPC分类号: C07D333/24 , C07D409/12 , C07D213/56 , C07D231/12 , C07D409/10 , C07D333/20 , C07C275/42 , A61K31/17 , A61K31/38 , A61K31/381 , A61K31/397 , A61K31/415 , A61K31/4418 , A61K31/4436 , A61K31/4535 , A61P35/02
-
公开(公告)号:EP3235819B1
公开(公告)日:2020-11-18
申请号:EP15869312.7
申请日:2015-12-15
申请人: Centaurus BioPharma Co., Ltd. , Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人: ZHU, Li , XIAO, Dengming , HU, Yuandong , DAI, Liguang , DUAN, Xiaowei , SUN, Yinghui , PENG, Yong , KONG, Fansheng , LUO, Hong , HAN, Yongxin , YANG, Ling , WANG, Shanchun
IPC分类号: C07D487/04 , A61K31/519 , A61K31/5377 , A61P35/00
-
公开(公告)号:EP3330263A1
公开(公告)日:2018-06-06
申请号:EP16829888.3
申请日:2016-07-29
申请人: Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人: WANG, Shulong , ZHAO, Na , LIU, Xijie , HU, Yuandong , ZHANG, Hui , LUO, Hong , PENG, Yong , XIAO, Dengming , HAN, Yongxin , ZHANG, Xiquan , TIAN, Xin
IPC分类号: C07D333/24 , C07D409/12 , C07D213/56 , C07C275/42 , C07D231/12 , C07D409/10 , C07D333/20 , A61P35/00 , A61P35/02
摘要: The present application relates to compounds represented by general formula (I), general formula (II) or general formula (III), and pharmaceutically acceptable salts or hydrates thereof, preparation methods thereof, and pharmaceutical compositions thereof. The compounds represented by general formula (I), general formula (II) or general formula (III) have inhibitory activities against isocitrate dehydrogenase 2 (IDH2), thereby being capable of treating IDH2 mutation-induced cancers.
-
公开(公告)号:EP3176160A1
公开(公告)日:2017-06-07
申请号:EP15826817.7
申请日:2015-07-31
申请人: Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人: GONG, Feng , LI, Xinlu , ZHAO, Rui , ZHANG, Xiquan , XU, Xinhe , LIU, Xijie , XIAO, Dengming , HAN, Yongxin
IPC分类号: C07D401/14 , C07D213/73 , A61K31/496 , A61K31/444 , A61P35/00
CPC分类号: C07D401/14 , A61K31/444 , A61K31/496 , C07D213/73
摘要: The present invention discloses pharmaceutically acceptable acid salts of pyridine-substituted 2-aminopyridine derivatives as protein kinase inhibitors, preparation methods, pharmaceutical compositions thereof, and use thereof for the treatment of diseases associated with protein kinase.
摘要翻译: 本发明公开了作为蛋白激酶抑制剂的吡啶取代的2-氨基吡啶衍生物的药学上可接受的酸式盐,其制备方法,药物组合物及其用于治疗与蛋白激酶相关的疾病的用途。
-
公开(公告)号:EP2952510A1
公开(公告)日:2015-12-09
申请号:EP14746385.5
申请日:2014-01-27
申请人: Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人: XIAO, Dengming , XU, Xinhe , LIU, Xijie , HU, Yuandong , YU, Honghao , LIU, Zhihua , PENG, Yong , SUN, Yinghui , LUO, Hong , KONG, Fansheng , HAN, Yongxin , SUN, Jian
IPC分类号: C07D401/04 , C07D213/74 , C07D401/06 , C07D401/14 , C07D213/73 , C07F9/6558 , A61K31/496 , A61K31/675 , A61K31/4545 , A61K31/5377 , A61K31/444 , A61K31/506 , A61P35/00
CPC分类号: C07D401/14 , A61K31/444 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61K31/675 , C07D213/73 , C07D213/74 , C07D401/04 , C07D401/06 , C07F9/65583
摘要: Disclosed are a 2-aminopyridine derivative having protein kinase inhibition activity, a preparation method and a pharmaceutical composition thereof Also disclosed are uses of the compounds and the pharmaceutical compositions thereof in the preparation of drugs for treating and/or preventing protein kinase-related diseases.
摘要翻译: 公开了具有蛋白激酶抑制活性的2-氨基吡啶衍生物,其制备方法和药物组合物。还公开了所述化合物及其药物组合物在制备用于治疗和/或预防蛋白激酶相关疾病的药物中的用途。
-
公开(公告)号:EP3330264B1
公开(公告)日:2020-05-06
申请号:EP16829879.2
申请日:2016-07-29
申请人: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人: GONG, Feng , LI, Xinlu , ZHAO, Rui , ZHANG, Xiquan , XU, Xinhe , LIU, Xijie , XIAO, Dengming , HAN, Yongxin
IPC分类号: C07D401/14 , A61K31/496 , A61P35/00
-
公开(公告)号:EP3330264A1
公开(公告)日:2018-06-06
申请号:EP16829879.2
申请日:2016-07-29
申请人: Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人: GONG, Feng , LI, Xinlu , ZHAO, Rui , ZHANG, Xiquan , XU, Xinhe , LIU, Xijie , XIAO, Dengming , HAN, Yongxin
IPC分类号: C07D401/14 , A61K31/496 , A61P35/00
摘要: The present invention discloses a crystal of citrate salt of pyridine-substituted 2-aminopyridine-based protein kinase inhibitors, in particular, to crystal of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4'-methoxy-6'-((S)-2-methylpiperazin -1-yl)-3,3'-bipyridin-6-amine citrate salt, a method for preparation thereof, a crystalline composition and a pharmaceutical composition comprising the crystal, and further discloses the use of crystals of citrate salt of the compound of Formula I in protein kinase-related diseases. The crystals of citrate salt according to the present invention are superior to 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4'-methoxy-6'-((S)-2-methylpiperazin-1-yl)-3,3'-bipyridin-6-amine or other salts of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4'-methoxy-6'-((S)-2-methylpiperazin-1-yl)-3,3'-bipyridin-6-amine in at least one aspect of bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, and the like.
-
公开(公告)号:EP2952510B1
公开(公告)日:2018-12-26
申请号:EP14746385.5
申请日:2014-01-27
申请人: Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人: XIAO, Dengming , XU, Xinhe , LIU, Xijie , HU, Yuandong , YU, Honghao , LIU, Zhihua , PENG, Yong , SUN, Yinghui , LUO, Hong , KONG, Fansheng , HAN, Yongxin , SUN, Jian
IPC分类号: C07D401/04 , C07D213/74 , C07D401/06 , C07D401/14 , C07D213/73 , C07F9/6558 , A61K31/496 , A61K31/675 , A61K31/4545 , A61K31/5377 , A61K31/444 , A61K31/506 , A61P35/00
CPC分类号: C07D401/14 , A61K31/444 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61K31/675 , C07D213/73 , C07D213/74 , C07D401/04 , C07D401/06 , C07F9/65583
摘要: Disclosed are a 2-aminopyridine derivative having protein kinase inhibition activity, a preparation method and a pharmaceutical composition thereof Also disclosed are uses of the compounds and the pharmaceutical compositions thereof in the preparation of drugs for treating and/or preventing protein kinase-related diseases.
-
-
-
-
-
-
-
-
-